NL-OMON44431撤回4 期
Effects of VERApamil versus metoprolol to prevent progression from Paroxysmal to persistent Atrial Fibrillation - VERAPAF
适应症
试验速览
- 阶段
- 4 期
- 状态
- 撤回
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •In order to be eligible to participate in this trial, a subject must meet all of the following criteria:
- •Patients (age >= 18) with symptomatic paroxysmal AF with an indication for rate control medication who participate in the RACE 5 registry. Patients must be able and willing to sign informed consent for the randomised study.
排除标准
- •Exclusion criteria are (history of) persistent AF, previous adverse effects to the study drugs, heart failure with reduced ejection fraction, symptomatic hypotension, atrioventricular conduction disturbance, severe asthma/COPD, history of pulmonary vein isolation (PVI), pregnancy and breastfeeding.
研究者
相似试验
尚未招募
不适用
EN: Which drug prevents worsening of paroxysmal atrial fibrillation: verapamil or metoprolol?NL: Welk medicijn voorkomt het hardnekkiger worden van paroxismaal atriumfibrilleren: verapamil of metoprolol?NL-OMON27565Martini ziekenhuis Groningen200
已完成
3 期
Effective of verapamil combination with vacuum for treatment of peyronie's diseasePeyronie disease.Disorder of penis, unspecifiedN48.9IRCT20200316046786N1Ahvaz University of Medical Sciences30
招募中
Unknown
The therapeutic effect of verapamil and triamcinolone along with macroneedling in the treatment of Peyronie's plaquePeyronie's plaque.N48.6Peyronie's diseaseIRCT20230408057854N1Shahid Beheshti University of Medical Sciences64
招募中
2 期
Comparing the prophylaxis effects of Metoprolol and Magnesium on prevention of AFatrial fibrillation after CABG ( coronary artery bypass graft)atrial fibrillation.Other specified complications of cardiac and vascular prosthetic devices, implants and graftsIRCT2016031520258N5Vice chancellor for research, Arak University of Medical Sciences195
进行中（未招募）
1 期
Treatment effects of Bisoprolol and Verapamil in symptomatic patients with non-obstructive hypertrophic cardiomyopathyon-obstructive hypertrophic cardiomyopathyCTIS2024-515346-17-00Aarhus Universitetshospital140